Icure Pharmaceutical Incorporation (175250) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Icure Pharmaceutical Incorporation (175250) has a cash flow conversion efficiency ratio of -0.055x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.28 Billion ≈ $-2.23 Million USD) by net assets (₩59.43 Billion ≈ $40.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 175250 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Icure Pharmaceutical Incorporation - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Icure Pharmaceutical Incorporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Icure Pharmaceutical Incorporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Icure Pharmaceutical Incorporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bactiguard Holding AB (publ)
ST:BACTI-B
|
-0.024x |
|
American Creek Resources Ltd
V:AMK
|
-0.114x |
|
NTPM Holdings Bhd
KLSE:5066
|
0.027x |
|
Northwest Copper Corp
V:NWST
|
-5.572x |
|
Nam Liong Global Corp
TWO:5450
|
0.048x |
|
Nila Spaces Limited
NSE:NILASPACES
|
-0.017x |
|
TAPEX INC
KO:055490
|
0.003x |
|
Nahar Industrial Enterprises Limited
NSE:NAHARINDUS
|
0.143x |
Annual Cash Flow Conversion Efficiency for Icure Pharmaceutical Incorporation (2015–2024)
The table below shows the annual cash flow conversion efficiency of Icure Pharmaceutical Incorporation from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Icure Pharmaceutical Incorporation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩60.26 Billion ≈ $40.84 Million |
₩-17.05 Billion ≈ $-11.56 Million |
-0.283x | -24.75% |
| 2023-12-31 | ₩59.59 Billion ≈ $40.39 Million |
₩-13.52 Billion ≈ $-9.16 Million |
-0.227x | -80.30% |
| 2022-12-31 | ₩89.67 Billion ≈ $60.77 Million |
₩-11.28 Billion ≈ $-7.65 Million |
-0.126x | +54.07% |
| 2021-12-31 | ₩95.76 Billion ≈ $64.89 Million |
₩-26.23 Billion ≈ $-17.77 Million |
-0.274x | -147.68% |
| 2020-12-31 | ₩112.15 Billion ≈ $76.01 Million |
₩-12.40 Billion ≈ $-8.41 Million |
-0.111x | -81.49% |
| 2019-12-31 | ₩97.53 Billion ≈ $66.10 Million |
₩-5.94 Billion ≈ $-4.03 Million |
-0.061x | +29.34% |
| 2018-12-31 | ₩84.69 Billion ≈ $57.40 Million |
₩-7.30 Billion ≈ $-4.95 Million |
-0.086x | -234.63% |
| 2017-12-31 | ₩17.47 Billion ≈ $11.84 Million |
₩1.12 Billion ≈ $758.55K |
0.064x | +122.24% |
| 2016-12-31 | ₩16.94 Billion ≈ $11.48 Million |
₩-4.88 Billion ≈ $-3.31 Million |
-0.288x | -741.49% |
| 2015-12-31 | ₩5.96 Billion ≈ $4.04 Million |
₩-204.05 Million ≈ $-138.28K |
-0.034x | -- |
About Icure Pharmaceutical Incorporation
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides … Read more